Association of acetylcholine receptor alpha-subunit gene expression in mixed thymoma with myasthenia gravis. 1999

A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
Institute of Pathology, University of Würzburg, Germany.

OBJECTIVE To investigate the association of MG with the transcription of muscular or neuronal acetylcholine receptor (AChR) subunit genes in thymomas. BACKGROUND Many steps in the pathogenesis of MG have been elucidated but, with rare exceptions, its etiology is unknown. In patients with MG with thymoma, the tumor probably elicits autoimmunity to AChR, but it is enigmatic why MG develops in some patients but not in others. METHODS Reverse transcriptase (RT)-PCR, immunohistochemistry, and immunofluorescence studies were carried out to investigate AChR expression in 35 patients with thymoma. Statistical analysis was used to specify significant differences between thymoma subtypes. RESULTS Considering all thymomas (n = 35), no correlation was found between MG status and AChR gene expression as detected by RT-PCR. However, when histologically defined thymoma subtypes were studied separately, transcription of the muscular AChR P3A- alpha-subunit gene was significantly associated (alpha < 0.01) with the occurrence of MG in mixed thymomas (n = 17), but not in thymomas of the cortical type. For the other muscular AChR subunits (P3A+ alpha isoform, beta, gamma, delta, and epsilon) and the alpha2 and beta4 neuronal AChR subunits, no such correlation was detected. CONCLUSIONS Expression of the P3A AChR alpha-subunit gene might be important for the pathogenesis of MG in mixed thymomas, suggesting etiologic heterogeneity of paraneoplastic MG among patients with histologically different thymoma subtypes.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013945 Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed) Carcinoma, Thymic,Carcinomas, Thymic,Thymic Carcinoma,Thymic Carcinomas,Thymomas
D013953 Thymus Neoplasms Tumors or cancer of the THYMUS GLAND. Cancer of Thymus,Thymus Cancer,Thymus Tumors,Cancer of the Thymus,Neoplasms, Thymic,Neoplasms, Thymus,Thymic Cancer,Thymic Neoplasms,Thymic Tumors,Cancer, Thymic,Cancer, Thymus,Cancers, Thymic,Cancers, Thymus,Neoplasm, Thymic,Neoplasm, Thymus,Thymic Cancers,Thymic Neoplasm,Thymic Tumor,Thymus Cancers,Thymus Neoplasm,Thymus Tumor,Tumor, Thymic,Tumor, Thymus,Tumors, Thymic,Tumors, Thymus
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
April 1996, Journal of autoimmunity,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
March 2011, Journal of the neurological sciences,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
May 1994, Proceedings of the National Academy of Sciences of the United States of America,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
August 2009, Muscle & nerve,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
July 1990, FEBS letters,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
May 1987, Journal of neurology,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
June 1988, FEBS letters,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
January 1994, Thymus,
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
April 1991, Journal of immunology (Baltimore, Md. : 1950),
A Wilisch, and S Gutsche, and V Hoffacker, and A Schultz, and S Tzartos, and W Nix, and B Schalke, and C Schneider, and H K Müller-Hermelink, and A Marx
February 1980, Neurology,
Copied contents to your clipboard!